Pulse Biosciences Shares Climb On Application for Percutaneous Electrode Review
By Sabela Ojea
Shares of Pulse Biosciences jumped on Tuesday after the company said that it submitted a Food and Drug Administration premarket application for its CellFX nsPFA percutaneous electrode.
Shares were recently up 15% at $7.19. The stock has surged 315% in the past twelve months.
Once the 510(k) application has been accepted, the FDA will conduct its review and may request additional information from the company based on that review, the immuno-oncology company developing an oncolytic electroceutical therapy said.
The FDA's guidance suggests the goal is to complete the 510(k) substantive review within 90 calendar days, Pulse Biosciences said.
"We look forward to collaborating with the FDA throughout the review process," Chief Executive Kevin Danahy said.
The 510(k) program accounts for most new medical devices the FDA reviews to reasonably assure their safety and effectiveness, according to the FDA's website.
CellFX nsPFA is designed for non-cardiac applications.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 21, 2023 12:14 ET (17:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks